Metropolis Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare reported strong consolidated revenue of ₹42,919 lakhs for Q2 FY26, up about 23% from ₹34,979 lakhs in Q2 FY25, driven by business acquisitions and organic growth. Profit after tax rose to ₹5,289 lakhs from ₹4,670 lakhs (up ~13% YoY). On a standalone basis, revenue grew ~11% to ₹35,571 lakhs and PAT rose ~10% to ₹4,663 lakhs. The Board declared an interim dividend of ₹4 per share (200% on face value of ₹2), with record date November 11, 2025. The company completed three pathology business acquisitions during the year (DAPIC, Scientific Metropolis, Ambika Pathology) totaling roughly ₹12,361 lakhs in consideration. Auditor BSR & Co. LLP issued an unmodified (clean) limited review report. On the tax front, the disputed income tax demand of ₹7,306 lakhs has been reduced to ₹3,880 lakhs with favorable appellate orders for 6 years.
Strong consolidated top-line growth and continued dividend payouts signal healthy operational momentum, though standalone growth is more modest. Clean auditor opinion and progress on tax disputes are positive for shareholders. Expect near-term stock reaction to be neutral-to-positive given steady growth and consistent dividend.